key: cord-0691616-ski1aika
authors: Farina, Antonio; Falso, Silvia; Cornacchini, Sara; Spagni, Gregorio; Monte, Gabriele; Mariottini, Alice; Massacesi, Luca; Barilaro, Alessandro; Evoli, Amelia; Damato, Valentina
title: Safety and tolerability of SARS‐Cov‐2 vaccination in patients with myasthenia gravis: A multicenter experience
date: 2022-04-17
journal: Eur J Neurol
DOI: 10.1111/ene.15348
sha: dfd70457533b21674cab2f0cf88f2b6c90f4899a
doc_id: 691616
cord_uid: ski1aika

BACKGROUND AND PURPOSE: During the COVID‐19 pandemic, myasthenia gravis (MG) patients have been identified as subjects at high risk of developing severe COVID‐19, and thus were offered vaccination with priority. The lack of direct data on the safety and tolerability of SARS‐CoV‐2 vaccines in MG have contributed to vaccine hesitancy. To address this issue, the safety and tolerability of SARS‐CoV‐2 vaccines were assessed in a large cohort of MG patients from two referral centers. METHODS: Patients with confirmed MG diagnosis, consecutively seen between October and December 2021 at two MG centers, were enrolled. Demographics, clinical characteristics, and information regarding SARS‐CoV‐2 infection/vaccination were extracted from medical reports and/or collected throughout telephonic or in‐person interviews. RESULTS: Ninety‐eight (94.2%) of 104 patients included were administered at least two vaccine doses 4 weeks before the interview or earlier, and among them, 63 of 98 (64.2%) have already received the “booster” dose. The most frequently used vaccines were BNT162b2‐Pfizer‐BioNTech and mRNA‐1273‐Moderna. Overall, only minor side effects were reported, most commonly local pain and fever. MG worsening after vaccination was observed in eight of 104 (7.7%) cases. The frequency of worsening among muscle‐specific tyrosine kinase MG cases (3/9, 33.3%) was significantly higher compared to other serological subgroups. Spontaneous symptom regression was observed in six of eight cases. Twelve of 104 (11.5%) patients had SARS‐CoV‐2 infection, and none of the SARS‐CoV‐2‐infected MG patients worsened after vaccination. CONCLUSIONS: Our data support the safety and tolerability of mRNA COVID‐19 vaccines, which should be strongly recommended in MG patients, who could be at higher risk of complications if exposed to SARS‐CoV‐2 infection.

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies (abs) targeting proteins at the motor end plate. Fatigable muscle weakness is its clinical hallmark and can involve ocular, limb, bulbar, and respiratory muscles, the latter resulting in respiratory failure [1] . Immunosuppression is the mainstay of MG therapy, and it is required in the majority of cases to achieve satisfactory symptom control [1] . As a drawback, patients are exposed to a significantly higher risk of infections, which are also well-known triggers of disease exacerbations [2] . For all these reasons, during the COVID-19 pandemic, MG patients have been identified as subjects at high risk of developing severe COVID-19, and thus were offered vaccination with priority. Nevertheless, in patients with autoimmune diseases, there may be concern that the vaccination itself can stimulate the immune system and trigger disease exacerbation [3] . There are no specific guidelines concerning vaccinations in patients with MG, but evidence shows that inactivated vaccines are safe in this population [4] . However, the lack of direct data on the safety and tolerability of SARS-CoV-2 vaccines in MG might contribute to vaccine hesitancy [5] . Therefore, we performed an observational study to investigate safety and risk of disease worsening of SARS-CoV-2 vaccines in a large cohort of consecutive MG patients from two referral centers.

We enrolled 114 patients with confirmed MG diagnosis, consecutively seen between October and December 2021 at the Neurology unit of Careggi Hospital of Florence (n = 62) and Gemelli Polyclinic Foundation of Rome (n = 52). Ten cases were excluded because they had not received vaccination at the time of evaluation.

Demographics, clinical characteristics, and information regarding SARS-CoV-2 infection and vaccination were extracted from medical reports and/or collected through telephonic or in-person interviews.

MG worsening was defined as the reoccurrence of any symptoms and signs of extraocular, bulbar, respiratory, axial, or limb muscle weakness lasting at least 24 h within the 4 weeks after SARS-CoV-2 infection or vaccination. The severity of MG was evaluated at the time of recruitment according to the Myasthenia Gravis Foundation of America (MGFA) clinical grading [6] , and the postintervention status (PIS) classification [7] was used to assess the clinical status at last follow-up after institution of the recorded treatment. Both were assessed by telephonic or in-person evaluation before and after vaccination. Acetylcholine receptor (AChR) and muscle-specific tyrosine kinase (MuSK) abs were tested at diagnosis by standard radioimmunoassay in all patients. Continuous and categorical variables were reported as mean (SD) and proportion (percentage), respectively.

Chi-squared test was used to compare categorical variables. All patients provided consent for the use of medical data for research purposes. The study was approved by the ethics committees of both institutions involved. Table S1 .

Ninety-eight of 104 (94.2%) patients were administered at least two vaccine doses 4 weeks before the interview or earlier, and among them, 63 of 98 (64.2%) have already received the "booster" dose ( Table 1) . In five cases, the vaccine type of the second dose was different from the first, and almost half of the patients (27/63, 42.8%) received a "booster" dose different from the first two doses. The most frequently used vaccines were BNT162b2-Pfizer-BioNTech and mRNA-1273-Moderna (see Table 1 for the frequency breakdown). Six patients, with a previous history of SARS-CoV-2 infection, received only one dose. Overall, only minor side effects were reported ( Table 1) , most commonly local pain (in 18.3%, 19.4%, and 20.6% of patients after the first, second, and third vaccine dose, respectively) and fever (in 4.8%, 11.2%, and 4.8% of patients after the first, second, and third dose, respectively).

Eighty-four of 104 (80.7%) patients were on immunotherapy at the time of the first dose, with oral corticosteroids being the most common treatment (69/104, 66.3%; Table 1 Table 2 ). These events were usually mild and occurred mostly after BNT162b2-Pfizer-BioNTech vaccine (7/8 cases). The frequency of worsening among MuSK-MG cases (3/9, 33.3%) was significantly higher compared with AChR-MG (4/83, 4.8%) and seronegative cases (1/12, 8.3%, p = 0.01; Table 2 ). In this subgroup, all patients but one (93.2%) were on immunotherapy at the time of the first vaccine dose. Spontaneous symptom regression was observed in six of eight cases. One seronegative MG patient presented with diplopia, limb weakness, and bulbar deficit, which required steroid increase after the second dose of Moderna; one MuSK-MG case presented with bulbar symptoms, which improved only partially after increasing steroids, whereas administration of intravenous immunoglobulins and rituximab led to complete symptom resolution. Overall, the outcome was favorable in all MG worsening cases, with no differences in the MGFA-PIS before vaccination and at last follow-up ( Table 2) . ported, and the frequency of both local pain and fever, which were the most frequently described in our cohort, is in line with previous studies in healthy individuals [12] . Only eight of 104 (7.7%) patients presented a worsening in MG symptoms within 4 weeks after the vaccine, which, however, was mostly mild and resolved spontaneously in 75% of cases. Moreover, the "booster" dose did not seem to be linked to an increased frequency of side effects or MG worsening. Caution might be warranted in patients with MuSK-MG, who, based on our findings, were more prone to experience MG worsening after COVID-19 vaccination. MuSK-MG subtype harbors defects in both central and peripheral B-cell tolerance checkpoints, and the major role seems to be played by plasmablasts [13] . It can be speculated that trigger factors could stimulate circulating autoreactive B cells and make MuSK-MG patients more susceptible than AChR-MG patients [13] . However, given the small number of patients with MuSK abs included, this result has to be confirmed in further studies. In general, for patients with MG, a case-by-case assessment is recommended, considering age, therapy, and previous response to vaccination. Moreover, this study's results apply to mRNA-based COVID-19 vaccines, given the very limited number of patients who received viral vector-based SARS-CoV-2 vaccines. Our data support the safety and tolerability of COVID-19 vaccination, which should be strongly recommended in MG patients, particularly in those at higher risk of complications when exposed to SARS-CoV-2 infection [14] . Further studies are needed to confirm these findings and to assess the efficacy of SARS-CoV-2 vaccines in MG patients under immunosuppressive therapy.

Open Access Funding provided by Universita degli Studi di Firenze within the CRUI-CARE Agreement.

None of the authors has any conflict of interest to disclose. 

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. 

Heterogeneity in myasthenia gravis: considerations for disease management

Myasthenia gravis and infectious disease

Vaccination of patients with autoimmune inflammatory rheumatic diseases

A prospective, doubleblind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis

To be or not to be vaccinated: that is a question in myasthenia gravis

Myasthenia gravis: recommendations for clinical research standards

International consensus guidance for management of myasthenia gravis

COVID-19 and generalized myasthenia gravis exacerbation: a case report

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

Committee the AQ and PS. Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders

COVID-19 vaccination in patients with myasthenia gravis: a single-center case series

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis

Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival